Emergence of Clostridium difficile-associated disease in North America and Europe

E. J. Kuijper, B. Coignard, P. Tüll, I. Poxton, J. Brazier, B. Duerden, M. Delmée, P. Mastrantonio, P. Gastmeier, F. Barbut, M. Rupnik, C. Suetens, A. Collignon, C. McDonald, D. N. Gerding, I. Tjallie van der Kooi, S. van den Hof, D. W. Notermans, A. Pearson, E. NagyA. Colville, M. Wilcox, P. Borriello, H. Pituch, N. Minton

Research output: Contribution to journalArticle

634 Citations (Scopus)

Abstract

The clinical spectrum of Clostridium difficile-associated disease (CDAD) ranges from diarrhoea to severe life-threatening pseudomembranous colitis. Although not always associated with previous antibiotic exposure, it is in the majority of cases. CDAD is recognised increasingly in a variety of animal species and in individuals previously not considered to be predisposed. C. difficile can be transmitted via personal contact or environmentally. The role of patients and healthcare workers who are symptom-free but colonised with C.difficile in the intestinal tract is unclear. C.difficile, with more than 150 PCR ribotypes and 24 toxinotypes, has a pathogenicity locus (PaLoc) with genes encoding enterotoxin A (tcdA) and cytotoxin B (tcdB). Genes for the binary toxin are located outside the PaLoc, but the role of this toxin is unclear. The recently completed genome sequence of C.difficile 630 revealed a large proportion of 11% of mobile genetic elements, mainly in the form of conjugative transposons. Diagnostic assays include tests for the detection of C.difficile products or genes and culture methods for isolation of a toxin-producing bacterium. Enzyme immunoassays to detect toxin in faeces are widely available, with varying sensitivities and specificities. Despite practical drawbacks and sensitivity less than 100%, the cell cytototoxicity assay is still considered to be the standard. Rapid diagnostic assays are available on a limited scale and require much improvement. Molecular tests enable the detection of carriers of toxigenic and non-toxigenic strains, as does culture. It is highly recommended to culture C.difficile from toxin-positive faeces samples and to store isolates for future characterisation and typing. The financial impact of CDAD on the healthcare system is substantial (€5-15000/case in England and $1.1billion/year in the USA). Assuming a European Union population of 457 million, the potential cost of CDAD can be estimated to be €3000million/year, and is expected to almost double over the next four decades. In North America, increasing rates of CDAD have been reported in Canada and the USA since March 2003, involving a more severe course, higher mortality, increased risk of relapse and more complications. This increased virulence is presumably associated with higher levels of toxin production by fluoroquinolone-resistant strains belonging to PCR ribotype 027, pulsed-field gel electrophoresis (PFGE) type NAP1, REA (restriction endonuclease analysis) type BI and toxinotype III. In Europe, outbreaks of CDAD due to the new, highly virulent strain of C.difficile PCR ribotype 027, toxinotype III have been recognised in 75 hospitals in England, 16 hospitals in The Netherlands, 13 healthcare facilities in Belgium and nine healthcare facilities in France. These outbreaks are very difficult to control, and preliminary results from case-control studies indicate a correlation with fluoroquinolones and cephalosporins. Information concerning community-acquired cases of ribotype 027 is lacking, and data concerning its incidence in nursing homes are limited. European countries should first develop early-warning and response capabilities at a national level. Depending on the nature of the notifications received, countries should implement laboratory-based or patient-based surveillance systems in specific, targeted populations.

Original languageEnglish
Pages (from-to)2-18
Number of pages17
JournalClinical Microbiology and Infection
Volume12
Issue number12 SUPPL. 6
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Clostridium difficile
North America
Ribotyping
Delivery of Health Care
Virulence
Fluoroquinolones
Feces
England
Polymerase Chain Reaction
Disease Outbreaks
Interspersed Repetitive Sequences
Genes
Pseudomembranous Enterocolitis
Pulsed Field Gel Electrophoresis
Enterotoxins
Belgium
DNA Restriction Enzymes
Cytotoxins
European Union
Cephalosporins

Keywords

  • CDAD
  • Clostridium difficile
  • ECDC
  • Emerging
  • ESGCD
  • Type O27

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Kuijper, E. J., Coignard, B., Tüll, P., Poxton, I., Brazier, J., Duerden, B., ... Minton, N. (2006). Emergence of Clostridium difficile-associated disease in North America and Europe. Clinical Microbiology and Infection, 12(12 SUPPL. 6), 2-18. https://doi.org/10.1111/j.1469-0691.2006.01580.x

Emergence of Clostridium difficile-associated disease in North America and Europe. / Kuijper, E. J.; Coignard, B.; Tüll, P.; Poxton, I.; Brazier, J.; Duerden, B.; Delmée, M.; Mastrantonio, P.; Gastmeier, P.; Barbut, F.; Rupnik, M.; Suetens, C.; Collignon, A.; McDonald, C.; Gerding, D. N.; Tjallie van der Kooi, I.; van den Hof, S.; Notermans, D. W.; Pearson, A.; Nagy, E.; Colville, A.; Wilcox, M.; Borriello, P.; Pituch, H.; Minton, N.

In: Clinical Microbiology and Infection, Vol. 12, No. 12 SUPPL. 6, 10.2006, p. 2-18.

Research output: Contribution to journalArticle

Kuijper, EJ, Coignard, B, Tüll, P, Poxton, I, Brazier, J, Duerden, B, Delmée, M, Mastrantonio, P, Gastmeier, P, Barbut, F, Rupnik, M, Suetens, C, Collignon, A, McDonald, C, Gerding, DN, Tjallie van der Kooi, I, van den Hof, S, Notermans, DW, Pearson, A, Nagy, E, Colville, A, Wilcox, M, Borriello, P, Pituch, H & Minton, N 2006, 'Emergence of Clostridium difficile-associated disease in North America and Europe', Clinical Microbiology and Infection, vol. 12, no. 12 SUPPL. 6, pp. 2-18. https://doi.org/10.1111/j.1469-0691.2006.01580.x
Kuijper, E. J. ; Coignard, B. ; Tüll, P. ; Poxton, I. ; Brazier, J. ; Duerden, B. ; Delmée, M. ; Mastrantonio, P. ; Gastmeier, P. ; Barbut, F. ; Rupnik, M. ; Suetens, C. ; Collignon, A. ; McDonald, C. ; Gerding, D. N. ; Tjallie van der Kooi, I. ; van den Hof, S. ; Notermans, D. W. ; Pearson, A. ; Nagy, E. ; Colville, A. ; Wilcox, M. ; Borriello, P. ; Pituch, H. ; Minton, N. / Emergence of Clostridium difficile-associated disease in North America and Europe. In: Clinical Microbiology and Infection. 2006 ; Vol. 12, No. 12 SUPPL. 6. pp. 2-18.
@article{84f2e78e595b4484aec5d92b53590108,
title = "Emergence of Clostridium difficile-associated disease in North America and Europe",
abstract = "The clinical spectrum of Clostridium difficile-associated disease (CDAD) ranges from diarrhoea to severe life-threatening pseudomembranous colitis. Although not always associated with previous antibiotic exposure, it is in the majority of cases. CDAD is recognised increasingly in a variety of animal species and in individuals previously not considered to be predisposed. C. difficile can be transmitted via personal contact or environmentally. The role of patients and healthcare workers who are symptom-free but colonised with C.difficile in the intestinal tract is unclear. C.difficile, with more than 150 PCR ribotypes and 24 toxinotypes, has a pathogenicity locus (PaLoc) with genes encoding enterotoxin A (tcdA) and cytotoxin B (tcdB). Genes for the binary toxin are located outside the PaLoc, but the role of this toxin is unclear. The recently completed genome sequence of C.difficile 630 revealed a large proportion of 11{\%} of mobile genetic elements, mainly in the form of conjugative transposons. Diagnostic assays include tests for the detection of C.difficile products or genes and culture methods for isolation of a toxin-producing bacterium. Enzyme immunoassays to detect toxin in faeces are widely available, with varying sensitivities and specificities. Despite practical drawbacks and sensitivity less than 100{\%}, the cell cytototoxicity assay is still considered to be the standard. Rapid diagnostic assays are available on a limited scale and require much improvement. Molecular tests enable the detection of carriers of toxigenic and non-toxigenic strains, as does culture. It is highly recommended to culture C.difficile from toxin-positive faeces samples and to store isolates for future characterisation and typing. The financial impact of CDAD on the healthcare system is substantial (€5-15000/case in England and $1.1billion/year in the USA). Assuming a European Union population of 457 million, the potential cost of CDAD can be estimated to be €3000million/year, and is expected to almost double over the next four decades. In North America, increasing rates of CDAD have been reported in Canada and the USA since March 2003, involving a more severe course, higher mortality, increased risk of relapse and more complications. This increased virulence is presumably associated with higher levels of toxin production by fluoroquinolone-resistant strains belonging to PCR ribotype 027, pulsed-field gel electrophoresis (PFGE) type NAP1, REA (restriction endonuclease analysis) type BI and toxinotype III. In Europe, outbreaks of CDAD due to the new, highly virulent strain of C.difficile PCR ribotype 027, toxinotype III have been recognised in 75 hospitals in England, 16 hospitals in The Netherlands, 13 healthcare facilities in Belgium and nine healthcare facilities in France. These outbreaks are very difficult to control, and preliminary results from case-control studies indicate a correlation with fluoroquinolones and cephalosporins. Information concerning community-acquired cases of ribotype 027 is lacking, and data concerning its incidence in nursing homes are limited. European countries should first develop early-warning and response capabilities at a national level. Depending on the nature of the notifications received, countries should implement laboratory-based or patient-based surveillance systems in specific, targeted populations.",
keywords = "CDAD, Clostridium difficile, ECDC, Emerging, ESGCD, Type O27",
author = "Kuijper, {E. J.} and B. Coignard and P. T{\"u}ll and I. Poxton and J. Brazier and B. Duerden and M. Delm{\'e}e and P. Mastrantonio and P. Gastmeier and F. Barbut and M. Rupnik and C. Suetens and A. Collignon and C. McDonald and Gerding, {D. N.} and {Tjallie van der Kooi}, I. and {van den Hof}, S. and Notermans, {D. W.} and A. Pearson and E. Nagy and A. Colville and M. Wilcox and P. Borriello and H. Pituch and N. Minton",
year = "2006",
month = "10",
doi = "10.1111/j.1469-0691.2006.01580.x",
language = "English",
volume = "12",
pages = "2--18",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "12 SUPPL. 6",

}

TY - JOUR

T1 - Emergence of Clostridium difficile-associated disease in North America and Europe

AU - Kuijper, E. J.

AU - Coignard, B.

AU - Tüll, P.

AU - Poxton, I.

AU - Brazier, J.

AU - Duerden, B.

AU - Delmée, M.

AU - Mastrantonio, P.

AU - Gastmeier, P.

AU - Barbut, F.

AU - Rupnik, M.

AU - Suetens, C.

AU - Collignon, A.

AU - McDonald, C.

AU - Gerding, D. N.

AU - Tjallie van der Kooi, I.

AU - van den Hof, S.

AU - Notermans, D. W.

AU - Pearson, A.

AU - Nagy, E.

AU - Colville, A.

AU - Wilcox, M.

AU - Borriello, P.

AU - Pituch, H.

AU - Minton, N.

PY - 2006/10

Y1 - 2006/10

N2 - The clinical spectrum of Clostridium difficile-associated disease (CDAD) ranges from diarrhoea to severe life-threatening pseudomembranous colitis. Although not always associated with previous antibiotic exposure, it is in the majority of cases. CDAD is recognised increasingly in a variety of animal species and in individuals previously not considered to be predisposed. C. difficile can be transmitted via personal contact or environmentally. The role of patients and healthcare workers who are symptom-free but colonised with C.difficile in the intestinal tract is unclear. C.difficile, with more than 150 PCR ribotypes and 24 toxinotypes, has a pathogenicity locus (PaLoc) with genes encoding enterotoxin A (tcdA) and cytotoxin B (tcdB). Genes for the binary toxin are located outside the PaLoc, but the role of this toxin is unclear. The recently completed genome sequence of C.difficile 630 revealed a large proportion of 11% of mobile genetic elements, mainly in the form of conjugative transposons. Diagnostic assays include tests for the detection of C.difficile products or genes and culture methods for isolation of a toxin-producing bacterium. Enzyme immunoassays to detect toxin in faeces are widely available, with varying sensitivities and specificities. Despite practical drawbacks and sensitivity less than 100%, the cell cytototoxicity assay is still considered to be the standard. Rapid diagnostic assays are available on a limited scale and require much improvement. Molecular tests enable the detection of carriers of toxigenic and non-toxigenic strains, as does culture. It is highly recommended to culture C.difficile from toxin-positive faeces samples and to store isolates for future characterisation and typing. The financial impact of CDAD on the healthcare system is substantial (€5-15000/case in England and $1.1billion/year in the USA). Assuming a European Union population of 457 million, the potential cost of CDAD can be estimated to be €3000million/year, and is expected to almost double over the next four decades. In North America, increasing rates of CDAD have been reported in Canada and the USA since March 2003, involving a more severe course, higher mortality, increased risk of relapse and more complications. This increased virulence is presumably associated with higher levels of toxin production by fluoroquinolone-resistant strains belonging to PCR ribotype 027, pulsed-field gel electrophoresis (PFGE) type NAP1, REA (restriction endonuclease analysis) type BI and toxinotype III. In Europe, outbreaks of CDAD due to the new, highly virulent strain of C.difficile PCR ribotype 027, toxinotype III have been recognised in 75 hospitals in England, 16 hospitals in The Netherlands, 13 healthcare facilities in Belgium and nine healthcare facilities in France. These outbreaks are very difficult to control, and preliminary results from case-control studies indicate a correlation with fluoroquinolones and cephalosporins. Information concerning community-acquired cases of ribotype 027 is lacking, and data concerning its incidence in nursing homes are limited. European countries should first develop early-warning and response capabilities at a national level. Depending on the nature of the notifications received, countries should implement laboratory-based or patient-based surveillance systems in specific, targeted populations.

AB - The clinical spectrum of Clostridium difficile-associated disease (CDAD) ranges from diarrhoea to severe life-threatening pseudomembranous colitis. Although not always associated with previous antibiotic exposure, it is in the majority of cases. CDAD is recognised increasingly in a variety of animal species and in individuals previously not considered to be predisposed. C. difficile can be transmitted via personal contact or environmentally. The role of patients and healthcare workers who are symptom-free but colonised with C.difficile in the intestinal tract is unclear. C.difficile, with more than 150 PCR ribotypes and 24 toxinotypes, has a pathogenicity locus (PaLoc) with genes encoding enterotoxin A (tcdA) and cytotoxin B (tcdB). Genes for the binary toxin are located outside the PaLoc, but the role of this toxin is unclear. The recently completed genome sequence of C.difficile 630 revealed a large proportion of 11% of mobile genetic elements, mainly in the form of conjugative transposons. Diagnostic assays include tests for the detection of C.difficile products or genes and culture methods for isolation of a toxin-producing bacterium. Enzyme immunoassays to detect toxin in faeces are widely available, with varying sensitivities and specificities. Despite practical drawbacks and sensitivity less than 100%, the cell cytototoxicity assay is still considered to be the standard. Rapid diagnostic assays are available on a limited scale and require much improvement. Molecular tests enable the detection of carriers of toxigenic and non-toxigenic strains, as does culture. It is highly recommended to culture C.difficile from toxin-positive faeces samples and to store isolates for future characterisation and typing. The financial impact of CDAD on the healthcare system is substantial (€5-15000/case in England and $1.1billion/year in the USA). Assuming a European Union population of 457 million, the potential cost of CDAD can be estimated to be €3000million/year, and is expected to almost double over the next four decades. In North America, increasing rates of CDAD have been reported in Canada and the USA since March 2003, involving a more severe course, higher mortality, increased risk of relapse and more complications. This increased virulence is presumably associated with higher levels of toxin production by fluoroquinolone-resistant strains belonging to PCR ribotype 027, pulsed-field gel electrophoresis (PFGE) type NAP1, REA (restriction endonuclease analysis) type BI and toxinotype III. In Europe, outbreaks of CDAD due to the new, highly virulent strain of C.difficile PCR ribotype 027, toxinotype III have been recognised in 75 hospitals in England, 16 hospitals in The Netherlands, 13 healthcare facilities in Belgium and nine healthcare facilities in France. These outbreaks are very difficult to control, and preliminary results from case-control studies indicate a correlation with fluoroquinolones and cephalosporins. Information concerning community-acquired cases of ribotype 027 is lacking, and data concerning its incidence in nursing homes are limited. European countries should first develop early-warning and response capabilities at a national level. Depending on the nature of the notifications received, countries should implement laboratory-based or patient-based surveillance systems in specific, targeted populations.

KW - CDAD

KW - Clostridium difficile

KW - ECDC

KW - Emerging

KW - ESGCD

KW - Type O27

UR - http://www.scopus.com/inward/record.url?scp=33748563622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748563622&partnerID=8YFLogxK

U2 - 10.1111/j.1469-0691.2006.01580.x

DO - 10.1111/j.1469-0691.2006.01580.x

M3 - Article

C2 - 16965399

AN - SCOPUS:33748563622

VL - 12

SP - 2

EP - 18

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 12 SUPPL. 6

ER -